Business
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7
About this update from Dbv Technologies Sa
Chatillon, France - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market : DBVT - CUSIP: 23306J309), a late-stage biopharmaceutical company, announced that VITESSE, its pivotal Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for the treatment of peanut-allergic children aged 4 to 7 years, met its primary endpoint. VIASKIN Peanut demonstrated a statistically significant treatment effect (p (C) 2025 Electronic News Publishing, source ENP Newswire
View stock analysis, news, and events for Dbv Technologies Sa